METHODS: To investigate potential efficacy for relieving nicotine withdrawal symptoms and promoting smoking abstinence, we conducted a randomized, double-blind, placebo-controlled, phase II study of once-a-day osmotic-release oral system methylphenidate (OROS-MPH, Concerta) at a target dose of __number__ -mg/day for __number__ weeks compared with placebo in __number__ adult cigarette smokers.